Tilray (NASDAQ:TLRY) Stock Price Down 1.1% - Time to Sell?

Tilray Inc (NASDAQ:TLRY - Get Free Report) was down 1.1% during trading on Thursday . The company traded as low as $1.22 and last traded at $1.25. Approximately 10,184,300 shares changed hands during trading, a decline of 60% from the average daily volume of 25,611,918 shares. The stock had previously closed at $1.26.

Analysts Set New Price Targets

Separately, Roth Mkm reduced their price target on shares of Tilray from $2.00 to $1.75 and set a "neutral" rating on the stock in a research report on Friday, October 11th.

Tilray Trading Down 4.0 %

The company has a 50-day moving average of $1.49 and a 200 day moving average of $1.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The company has a market cap of $1.09 billion, a PE ratio of -4.48 and a beta of 2.08.

Tilray (NASDAQ:TLRY - Get Free Report) last announced its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting analysts' consensus estimates of ($0.04). The firm had revenue of $200.00 million during the quarter, compared to analysts' expectations of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The company's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.10) EPS. Analysts predict that Tilray Inc will post -0.14 earnings per share for the current year.

Insider Activity

In other Tilray news, CFO Carl A. Merton purchased 26,000 shares of the firm's stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the purchase, the chief financial officer now owns 26,000 shares of the company's stock, valued at approximately $35,360. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.87% of the company's stock.

Institutional Trading of Tilray

Hedge funds and other institutional investors have recently bought and sold shares of the business. Synovus Financial Corp boosted its stake in shares of Tilray by 176.7% during the third quarter. Synovus Financial Corp now owns 36,092 shares of the company's stock valued at $64,000 after purchasing an additional 23,046 shares during the period. Barclays PLC boosted its position in Tilray by 600.4% in the 3rd quarter. Barclays PLC now owns 204,144 shares of the company's stock valued at $359,000 after buying an additional 174,997 shares during the period. Toronto Dominion Bank boosted its position in Tilray by 454.5% in the 3rd quarter. Toronto Dominion Bank now owns 128,923 shares of the company's stock valued at $227,000 after buying an additional 105,671 shares during the period. XTX Topco Ltd grew its stake in Tilray by 1,079.7% in the 3rd quarter. XTX Topco Ltd now owns 281,504 shares of the company's stock worth $495,000 after acquiring an additional 257,641 shares in the last quarter. Finally, State Street Corp increased its position in shares of Tilray by 4.7% during the third quarter. State Street Corp now owns 1,961,338 shares of the company's stock worth $3,452,000 after acquiring an additional 88,079 shares during the period. Hedge funds and other institutional investors own 9.35% of the company's stock.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.